Joel Greenblatt’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-175,564
Closed -$1.54M – 1911
2026
Q2
$1.54M Buy
175,564
+163,427
+1,347% +$1.24M ﹤0.01% 1233
2026
Q1
$93.1K Buy
+12,137
New +$83.1K ﹤0.01% 1725
2025
Q3
– Sell
-16,224
Closed -$42.8K – 1749
2025
Q2
$42.8K Sell
16,224
-28,781
-64% -$77.4K ﹤0.01% 1649
2025
Q1
$135K Buy
+45,005
New +$136K ﹤0.01% 1494
2024
Q3
– Sell
-14,594
Closed -$92.2K – 1471
2024
Q2
$92.2K Sell
14,594
-17,932
-55% -$118K ﹤0.01% 1384
2024
Q1
$175K Buy
32,526
+21,738
+202% +$98.4K ﹤0.01% 1299
2023
Q4
$54.2K Buy
+10,788
New +$33.9K ﹤0.01% 1308
2020
Q3
– Sell
-27,855
Closed -$342K – 1083
2020
Q2
$342K Buy
+27,855
New +$157K 0.01% 834
2017
Q3
– Sell
-13,766
Closed -$104K – 969
2017
Q2
$104K Buy
+13,766
New +$59.5K ﹤0.01% 929

Other funds holding IBRX

Joel Greenblatt's IBRX Position: Q3 2026 in Review

Joel Greenblatt sold out of ImmunityBio (IBRX) in Q3 2026, closing a stake of 175,564 shares — an estimated $1.54M sold.

Joel Greenblatt first reported a position in IBRX in Q2 2017 and held it in 9 quarters. The position peaked at $1.54M in Q2 2026. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Joel Greenblatt reported no remaining ImmunityBio position as of Q3 2026 after selling out during the quarter.
  • Joel Greenblatt sold 175,564 ImmunityBio shares in Q3 2026, an estimated $1.54M.
  • Joel Greenblatt first reported a position in ImmunityBio in Q2 2017 and held it in 9 quarters.
  • Joel Greenblatt's ImmunityBio position peaked at $1.54M in Q2 2026.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.